DOCSLIB.ORG

Field Trials for GM Food Get Green Light in India

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Field Trials for GM Food Get Green Light in India NATURE|Vol 448|23 August 2007 NEWS IN BRIEF Field trials for GM food Asthmatics win payment in diesel-fumes lawsuit get green light in India Asthma patients in Tokyo last week welcomed a cash settlement India’s first genetically modified (GM) food from car manufacturers and crop is a step closer to reaching the dining the Japanese government. The table. The government has approved field one-time payment resolved a trials for a strain of brinjal (aubergine) decade-long legal battle in which carrying a Bt (Bacillus thuringiensis) gene. the asthmatics blamed diesel car Jalna-based Mahyco, the Indian venture fumes for their illness. KIM KYUNG-HOON/REUTERS of US seed giant Monsanto, claims its insect- The automakers, including resistant variety gives better yields with Toyota, Honda and Nissan, will less pesticide use. To avoid possible cross- provide ¥1.2 billion (US$10.5 contamination with farmers’ crops, the trials million) to the plaintiffs, and a will be carried out in government farms. further ¥3.3 billion to support But critics already campaigning against Bt a five-year health plan for the cotton — currently the only GM crop grown patients. The central government in India — say the brinjal trials are illegal. and Tokyo metropolitan Full biosafety data on the brinjal tests government will each contribute ¥6 billion to the medical programme. have not yet been generated, says Kavitha Kuruganti of the Centre for Sustainable scientists — to pay for relocation, housing starting dose “should be considered for Agriculture, based in Hyderabad: “The trials and research. “This is about the rescue of patients with certain genetic variations”. would open doors for entry of GM tomato, science and learning,” says Goodman. Warfarin is widely used in patients with okra, mustard, corn, rice and five other food artificial heart valves and those at risk crops in the pipeline.” The government says of blood clots. But it can cause massive that a committee of experts reviewed all WWF sues over threat to and sometimes fatal bleeding. The two available biosafety data and concluded they endangered whales gene variants flagged by the FDA encode were in order. enzymes involved in warfarin’s breakdown Last month, in the Sea of Okhotsk, Russia, and its function as an anticlotting agent. a conglomerate of energy firms lowered Although the FDA has demanded similar Gates Foundation helps a 28,000-tonne platform for drilling for labelling on four other drugs, warfarin Iraqis escape the conflict oil on to a base on the sea floor. They did is the first major drug to be labelled in it very carefully — in part to keep down this way. “This means that personalized The Bill & Melinda Gates Foundation the noise, as the last feeding grounds of medicine is no longer an abstract concept is getting into the business of helping the western Pacific population of grey but has moved into the mainstream,” says persecuted Iraqi academics continue their whales (Eschrichtius robustus) lie some Larry Lesko, director of the FDA’s Office of research abroad. A $5-million grant will 7 kilometres away. Clinical Pharmacology. help support the Scholar Rescue Fund run But environmentalists and some by the Institute for International Education scientists say construction of the platform (IIE), which aims to raise $15 million for was not quiet enough. So the environmental India to expand research Iraq. group WWF and activist group the Corner institutes and universities The Gates Foundation is best known for House have taken legal action against a its $33-billion bankroll and for tackling UK government department. The WWF The Indian Planning Commission has health problems such as malaria and HIV. claims that the department conditionally rolled out a seven-year plan to set up eight The new grant is a one-time award, not a promised financial support for part of the more Institutes of Technology — the élite shift in focus, says a spokesperson for the Sakhalin-II project without approving its science and technology universities. Also in foundation. environmental impact. the US$32-billion plan are 7 new national As Iraqi professors come under increasing A department spokesperson calls the business schools and 20 Institutes of threat of violence, many have sought case “flimsy” and points out that the Information Technology. help to temporarily flee the country, says environmental review was in fact one of the The push follows a call by Prime Minister IIE president Allan Goodman. So far, 41 conditions that would have to be met for Manmohan Singh to put Indian science on grants have been awarded to Iraqis — 27 to approval. It is estimated that the Okhotsk the global map by upgrading its research region harbours the equivalent of 45 billion facilities. There are also plans for 30 more barrels of oil. ‘central universities’ — one in each of the 16 states with no such institution at present, Anticlotting agent gets and 14 in states that offer free land. Notice to authors and readers gene-specific label change Nature and the Nature journals have refined their policy on competing financial interests. MOHAMMED AMEEN/REUTERS The US Food and Drug Administration Nature requires that all authors declare that they (FDA) is changing the label on a widely used do or do not have competing financial interests drug to include information about how two relevant to their submission. If an article in Nature genes may affect dosage requirements. does not contain such a statement, readers can The FDA said on 16 August that the label assume that authors declared to the editors that on warfarin, a popular blood-thinner with they have no competing financial interests. See www.nature.com/authors/editorial_policies/ Car-bomb wreckage near Baghdad University the trade name Coumadin, is to be revised. competing.html for full details of the policy. highlights the perils for some Iraqi academics. The new version will state that a lower 851.
Load more

Recommended publications
  • Biohazardous Waste Treatment
    Biological Safety: Principles & Applications for Lab Personnel Presented by: Biological Safety Office http://biosafety.utk.edu Introduction OVERVIEW OF BIOSAFETY PROGRAM Introduction to Laboratory Safety When entering the laboratory environment you are likely to contact hazards that you would not encounter on a daily basis. These can include: • Physical hazards • Chemical hazards • Radiological hazards • Biological hazards Biohazards Any biological agent or condition that poses a threat to human, animal, or plant health, or to the environment. Examples include, but not limited to: • Agents causing disease in humans, animals or plants (bacteria, viruses, etc.) • Toxins of biological origin • Materials potentially containing infectious agents or biohazards .Blood, tissues, body fluids etc. .Waste, carcasses etc. • Recombinant DNA (depends) • Nanoparticles w/biological effector conjugates (depends) Types of Biohazards: What they are.... How they’ll look.... Regulations & Standards The Institutional Biosafety Committee Institutional Biosafety Committees (IBC) are required by the National Institutes of Health Office of Biological Activities (NIH; OBA) for institutions that receive NIH funding and conduct research using recombinant or synthetic nucleic acids. The UT IBC is composed of 14 UT-affiliated members and 2 non-affiliated members, who collectively offer a broad range of experience in research, safety and public health. Functions of the IBC Projects requiring IBC review • Performing both initial and annual • Those involving recombinant
    [Show full text]
  • A New Level 3 Biosafety and Astrobiology Laboratory in Pieve A
    PAN.R.C.- A New Level 3 Biosafety and Astrobiology Laboratory in Pieve a Nievole (PT) Tasselli, D. TS Corporation Srl - Astronomy and Astrophysics Department Via Rugantino, 71, 00169 Roma RM - Italy E-mail:[email protected] Ferrara, G. TS Corporation Srl - Biology Department Via Cavalcanti, 10, 51010 Massa e Cozzile PT - Italy E-mail:[email protected] Ricci, S. TS Corporation Srl - Meteorogical and Climatic Change Department Via Rugantino, 71, 00169 Roma RM - Italy E-mail:[email protected] Bianchi, P. TS Corporation Srl - Geology and Geophysics Department Via Rugantino, 71, 00169 Roma RM - Italy E-mail:[email protected] Abstract We report our proposal for the establishment of a biocontainment and astrobiology laboratory in a strategic area of Pieve a Nievole (PT) at 28 mt above sea level - to face the lack of biological and astrobiological research centers and all the social, economic and cultural consequences that this project implicate. The structure will be built under the Horizon 2020 work program 2018-2020 - European Research Infrastructures (in- cluding e-Infrastructures), and will enable the development of major re- arXiv:1811.05201v1 [astro-ph.IM] 13 Nov 2018 search project. Keyword: astrobiology - biosafety - biosecurity - BSL3 - containment - research center - biological risk - biological agents - new research facility - location: Pieve a Nievole (PT) This paper was prepared with the LATEX 1 1 Introduction project that involves the use of biological agents from second or third group, must The environment that surrounds us is pop- ask permission and wait for the technical ulated by biological agents such as bacte- time to use the currently available facili- ria, viruses or fungi.
    [Show full text]
  • Genetically Modified Tree Policy Technology and Innovation, Sustainability Issued By: Date: 18/06/2021 and Institutional Affairs Code: POL.00.0044 Revision
    Title: Genetically Modified Tree Policy Technology and Innovation, Sustainability Issued by: Date: 18/06/2021 and Institutional Affairs Code: POL.00.0044 Revision: Contents 1 PURPOSE ............................................................................................................................................................. 3 2 REFERENCE DOCUMENTS ................................................................................................................................. 4 3 TERMS, DEFINITIONS AND ABBREVIATIONS .................................................................................................. 4 4 GUIDELINES ........................................................................................................................................................ 8 4.1 Principles ......................................................................................................................................................... 8 4.2 Governance and Ethics .................................................................................................................................. 9 4.2.1 Advisory Committee .................................................................................................................................. 9 4.2.1.1 Purpose ..................................................................................................................................................... 9 4.2.1.2 Responsibilities .......................................................................................................................................
    [Show full text]
  • Biosafety Manual
    Office of Environment, Health & Safety Biosafety Manual Table of Contents Introduction 2 Institutional Review of Biological Research 3 Introduction to CLEB 3 Prerequisites to Initiation of Work 3 Completion and Submission of the BUA Application 4 Committee Review and Approval of Applications 7 Amending the BUA 9 Risk Assessment 10 Classification of Agents by Risk Group 10 Recombinant DNA 11 Risk Factors of the Agents 13 Exposure Sources 13 Containment of Biological Agents 15 Biosafety Levels 15 Practices and Procedures 16 Engineering Controls 19 Waste Disposal 23 Emergency Plans and Reporting 25 Spill Cleanup Procedures 25 Exposure Response Protocols 28 Reporting 28 Appendix 1: Working with Viral Vectors 29 Adenovirus 32 Adeno-associated Virus 34 Lentivirus 35 Moloney Murine Leukemia Virus (MoMuLV or MMLV) 37 Rabies virus 38 Sendai virus 41 References 42 Appendix 2: Important Contact Information 43 Appendix 3: Bloodborne Pathogen Considerations 44 Appendix 4: Useful Resources 45 1 Section I. Introduction UC Berkeley is committed to maintaining a healthy and safe workplace for all laboratory workers, students and visitors. This manual is an overview of the administrative steps necessary to obtain and maintain approval for the use of biological materials in laboratories, as well as a reference for good work prac- tices and safe handling of other potentially infectious materials (OPIM). A variety of procedures are conducted on campus which use many different agents. This manual addresses the biological hazards frequently encountered in labora- tories. Biological hazards include infectious or toxic microorganisms (including viral vectors), potentially infectious human substances, and research animals and their tissues, in cases from which transmission of infectious agents or tox- ins is reasonably anticipated.
    [Show full text]
  • FORESTS and GENETICALLY MODIFIED TREES FORESTS and GENETICALLY MODIFIED TREES
    FORESTS and GENETICALLY MODIFIED TREES FORESTS and GENETICALLY MODIFIED TREES FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 2010 The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO in preference to others of a similar nature that are not mentioned. The views expressed in this information product are those of the author(s) and do not necessarily reflect the views of FAO. All rights reserved. FAO encourages the reproduction and dissemination of material in this information product. Non-commercial uses will be authorized free of charge, upon request. Reproduction for resale or other commercial purposes, including educational purposes, may incur fees. Applications for permission to reproduce or disseminate FAO copyright materials, and all queries concerning rights and licences, should be addressed by e-mail to [email protected] or to the Chief, Publishing Policy and Support Branch, Office of Knowledge Exchange, Research and Extension, FAO, Viale delle Terme di Caracalla, 00153 Rome, Italy. © FAO 2010 iii Contents Foreword iv Contributors vi Acronyms ix Part 1. THE SCIENCE OF GENETIC MODIFICATION IN FOREST TREES 1. Genetic modification as a component of forest biotechnology 3 C.
    [Show full text]
  • The Basics of Biocontainment
    technology feature The basics of biocontainment Studying potentially dangerous microbes in animal models of the disease they cause takes some extra considerations, as researchers and staf must perform their work under the careful restrictions of diferent biosafety level laboratories. Jim Kling n early 2020, when the first concerns arose about a SARS-CoV-2 pandemic, Iresearchers at biosafety facilities realized they would soon be pivoting to work with the novel coronavirus. Fortunately, many had previous experience to draw on, such as working with influenza virus or other airborne pathogens, or with SARS-CoV-1. That 2002 outbreak resulted in a more severe, though less transmissible, disease than the current virus. Preprints from Chinese and Asian researchers guided early efforts, said Kenneth Palmer, director of the University of Louisville (UoL) Regional Biocontainment Laboratory and the UofL Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases. The team in Kentucky had also established a ferret model during their Keeping microbes, such as SARS-CoV-2, contained is a critical consideration for those studying work with SARS-CoV-1. “We found that dangerous agents in biosafety facilities. Credit: E. Dewalt, Springer Nature our experience with the ferret model of SARS-CoV-1 was very similar to the published experience [with SARS-CoV-2], and the procedures we are using for research are tiered from biosafety level (BSL) 1 to are reserved for agents with a high fatality are very similar between SARS-CoV1 4. BSL-1 can be used for agents that don’t rate, such as Ebola. They require full body and SARS-CoV2, and avian influenza consistently cause disease.
    [Show full text]
  • Bi F T Osafety for Biosafety for Clinical Laboratories for Clinical Laboratories
    Biosa fe ty for Clinical Laboratories 1 Biosafety: Preventing Lab Acquired Infections . July 15, 2000. Alabama microbiologist, 35 y/o was evaluated in the ER for malaise, fever, myalgia. July 16, tech became tachycardic and hypotensive, died within hours. Cause???... 2 Biosafety: Preventing Lab Acquired Infections Neisseria meningitidis 3 Possible exposure to N. meningitidis . Prepared a Gram stain from the blood culture of a patient . Aspiration from blood cultures was performed on the open bench; biosafety cabinets, eye protection, or masks were not used routinely for this procedure. Patient subsequently shown to have meningococcal disease. 4 Biosafety in Clinical Laboratories WhyisitWhy is it important? Because of where you work and what you do… 5 Objectives . Discuss the importance of biosafety in the clinical laboratory . Describe recommendations for preventing Laboratory Acquired Infections. Describe the four biosafety levels . List Standard Microbiological Practices in a BSL-2 and BSL-3 laboratories . Describe special practices in BSL-2 and BSL-3 laboratories . Understand how to work safely in a biological safety cabinet (BSC) 6 What is Biosafety? The combination of work practices, ppyrimary containment devices, and laboratory design to reduce the risk of laboratory infection or release of a microbe to the environment. 7 Princippyles of Biosafety Good biosafety practices prevent occupationally acquired infections by: Intercepting microorganisms before they can infect you (block routes of transmission) and breaking the “chain of infection” 8 Chain of Infection Reservoir of pathogen X Portal of escape X Transmission X Route of entry/infectious dose X Susceptible host X Incubation period X Infection 9 PORTALS OF ENTRY OF BIOLOGICAL AGENTS MUCOUS MEMBRANES RESPIRATORY TRACT (LUNGS) GASTROINTESTINAL TRACT SKIN 10 Standard (Universal) Precautions .
    [Show full text]
  • Biological Safety in Laboratories the CHALLENGE
    Biological Safety in laboratories THE CHALLENGE Safe Labs • What is ‘safe’? • Who decides? • How to inform occupants? • How to manage change? LAB/RESEARCH COMMUNITY SAFETY Involves & relies on •Teaching •Laboratory •Research Laboratories Research Field •Radiation & Bio •Chemical •Fire Prevention, Building Design & Safety Officers Hygiene Officer 3 Maintenance, Industrial Hygienists etc. • EVERYONE is responsible for quality and safety SAFETY, HEALTH & ENVIRONMENTAL GOALS ZERO… • Workplace injuries • Workplace illnesses • Related injury/illness at home • Property loss • Unintended environmental damage MANAGEMENT OF HEALTH, SAFETY AND THE ENVIRONMENT . Achieving excellence in providing a healthy and safe working environment . Supporting environmentally sound practices in the conduct of University activities . Comply with all applicable health, safety, and environmental protection laws, regulations and requirements BIOLOGICAL RESEARCH IS ANY EXPERIMENTAL ACTIVITY INVOLVING THE FOLLOWING BIOLOGICAL AGENTS: • Human source materials (includes primary and immortal cell lines, clinical specimens, samples, tissues, etc) • Animals and animal source materials • Plants and plant source materials • Recombinant and synthetic DNA/RNA (including all viral vectors, RNAi technologies, etc). • Microorganisms (bacteria, viruses, fungi, prions, yeast, algae, rickettsiae, parasites, etc) • Biological toxins, allergens The CDC Biosafety in Microbiological and Biomedical Laboratories (BMBL) classifies risk group agents to: RG1 Agent not associated with disease in healthy adult humans e.g. Bacillus subtilis RG2 Associated with human disease which is rarely serious and preventive or therapeutic interventions are often available e.g.Staphylococcus aureus, influenza viruses type A, B, and C RG3 Serious or lethal human disease; preventive or therapeutic interventions may be available e.g. Mycobacterium tuberculosis •RG4 Serious or lethal human disease; preventive or therapeutic interventions are usually not available e.g.
    [Show full text]
  • Biosafety Levels (US)
    ! "#$%&'()*!+(,(-%!./01! ________________________________________________________________ !BIOSAFETY LEVEL 1 ."0+231 practices and procedures are suitable for work involving agents of no known or of minimal potential hazard to laboratory personnel and the environment. Work is performed with defined and characterized strains of viable microorganisms not known to cause disease in healthy individuals, although there are some agents in this category, which are termed opportunistic and may cause disease in compromised individuals (e.g., in immunosuppressed individuals, in the aged or in infants). In general at this level, 31 the laboratory is not separated from the general traffic patterns of others, 41 work is 5(6(7&--*! performed on open bench tops,! 81 special containment equipment and devices are not 9%9&--* needed, :1 laboratory personnel have specific training in the procedures conducted in the laboratory and are supervised by personnel with general training in microbiology or related field. !BIOSAFETY LEVEL 2 ."0+241!practices and procedures are suitable for work involving agents of moderate potential risk to personnel and the environment. These agents can cause disease in healthy individuals and pose a moderate risk to the environment. Precautions for use of these agents include BSL-1 practices plus, 31 access to the laboratory is limited when work with these organisms is being performed, 41 the use of biological safety cabinets or protective equipment is recommended when performing work which can cause the potential for generation of aerosols (pipeting, centrifugation procedures, vortexing, etc.), 81 laboratory personnel have specific training in handling pathogenic materials, are familiar with the hazards associated with the specific agents they are using, and are directed by scientists who are competent and familiar with good microbiological practices.
    [Show full text]
  • Ebola and Marburg Virus Disease Epidemics: Preparedness, Alert, Control and Evaluation
    EBOLA STRATEGY Ebola and Marburg virus disease epidemics: preparedness, alert, control and evaluation August 2014 © World Health Organization 2014. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. WHO/HSE/PED/CED/2014.05 Contents Acknowledgements ............................................................................................................ 5 List of abbreviations and acronyms ................................................................................... 6 Chapter 1 – Introduction .................................................................................................... 7 1.1 Purpose of the document and target audience ....................................................................
    [Show full text]
  • BMBL) Quickly Became the Cornerstone of Biosafety Practice and Policy in the United States Upon First Publication in 1984
    Biosafety in Microbiological and Biomedical Laboratories 5th Edition U.S. Department of Health and Human Services Public Health Service Centers for Disease Control and Prevention National Institutes of Health HHS Publication No. (CDC) 21-1112 Revised December 2009 Foreword Biosafety in Microbiological and Biomedical Laboratories (BMBL) quickly became the cornerstone of biosafety practice and policy in the United States upon first publication in 1984. Historically, the information in this publication has been advisory is nature even though legislation and regulation, in some circumstances, have overtaken it and made compliance with the guidance provided mandatory. We wish to emphasize that the 5th edition of the BMBL remains an advisory document recommending best practices for the safe conduct of work in biomedical and clinical laboratories from a biosafety perspective, and is not intended as a regulatory document though we recognize that it will be used that way by some. This edition of the BMBL includes additional sections, expanded sections on the principles and practices of biosafety and risk assessment; and revised agent summary statements and appendices. We worked to harmonize the recommendations included in this edition with guidance issued and regulations promulgated by other federal agencies. Wherever possible, we clarified both the language and intent of the information provided. The events of September 11, 2001, and the anthrax attacks in October of that year re-shaped and changed, forever, the way we manage and conduct work
    [Show full text]
  • US Government Efforts to Improve Biosafety and Biosecurity
    U.S. Government Efforts to Improve Biosafety and Biosecurity Science saves lives. For public health and health care, scientific research aims to protect Americans from infectious diseases that can harm people, animals, plants, the environment, and the economy. Conducting such research safely and securely is as critical as the research itself. Researchers from academia, private industry, and government agencies have made great strides in improving the safety and security of life sciences research using federal policies and procedures that can adapt quickly as science and technology evolves. Biosafety and biosecurity have long been important federal missions – and since 2015, the federal government agencies involved in life sciences research have collaborated on Oversight of Select Agents and Toxins innovative reforms to improve key aspects of biosafety and Effective oversight of biological select agents and toxins biosecurity. requires proper inventory control and management programs at the institutional and laboratory levels where Laboratory Biosafety is the use of specific research is conducted and where biological select agents and practices, safety equipment, and specially designed toxins are handled or stored. Oversight of these management buildings and laboratories to ensure that workers, the programs must be supported from top management within community, and the environment are protected from each organization. Guidance on Ensuring Institutional infectious agents and toxins and biological hazards. Compliance with Biosafety, Biocontainment,
    [Show full text]